沙美特罗替卡松粉联合孟鲁司特治疗学龄前儿童哮喘

摘要

目的：比较沙美特罗替卡松粉吸入剂联合孟鲁司特与单用沙美特罗替卡松吸入剂治疗儿童中度哮喘的有效性。方法：将80例患中度间歇性哮喘的学龄前儿童（3~5岁）随机分成两组，治疗组使用沙美特罗替卡松吸入剂50/100μg（葛兰素史克公司生产），每12小时吸入1次，孟鲁司特钠4 mg（杭州默沙东）晨起顿服1粒；对照组单用沙美特罗替卡松吸入剂50/100μg（葛兰素史克公司生产），每12小时吸入1次，两组用药后均用温水漱口。治疗3个月后评价两组患儿呼气峰流速值（PEFR）的变化及哮喘日夜症状评分。结果：治疗3个月后，与对照组相比，治疗组 PEFR 值占预计值的百分比与对照组相比明显改善（P<0.05），且治疗组的临床症状评分明显优于对照组（P<0.01）。结论：应用沙美特罗替卡松吸入剂和孟鲁司特片联合治疗学龄前儿童哮喘能更迅速改善临床症状和肺功能，可显著提高治疗儿童哮喘的疗效。%Objective:To compare the effectiveness of Salmeterol Fluticasone Powder Inhalant combined with Montelukast and single Salmeterol Fluticasone powder inhalant.Method:80 cases with moderate intermittent asthma in preschool childen(aged 3-5)were randomly divided into two groups. The trial group with Salmeterol Fluticasone powder inhalant 50/100 μg(GlaxoSmithKline Co.)for each 12 h inhalation time,Montelukast 4mg (Hangzhou MSD)morning meal in a suit;the control group only used Salmeterol Fluticasone powder inhalant 50/100 μg(GlaxoSmithKline Co.)for each 12 h inhalation time. The two groups were gargle with warm water after treatment.After treatment,compared lung function and asthma control test score of two groups,and observed adverde reactiond. Result:After 3 months of treatment,the treatment group compared with the control group,in treatment group,PEFR value of the percentage of predicted value compared with the control group improved significantly(P<0.05),the clinical symptoms and the treatment group was significantly better than the control group(P<0.01).Conclusion:Salmeterol inhalation fluticasone and montelukast tablets pre -school children asthma combination therapy is more rapid improvement in clinical symptoms and lung function,can significantly improve the efficacy of the treatment of children with asthma.